iOnctura expands clinical trial programme for NSCLC
July 9, 2024Research and Development NSCLC, Oncology, clinical trial, iOnctura, lung cancer
iOnctura has announced the expansion of its clinical trial programme for its lead pipeline asset, roginolisib.
Roche gains CE Mark for AI glucose monitoring system for diabetes management
July 9, 2024Medical Communications AI, Diabetes, Roche, diabetes, glucose monitoring
Roche has announced that it has received the CE Mark for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution.
Oxolife shares data from phase 2 trial for infertility drug
July 8, 2024Research and Development Oxolife, Reproductive health, clinical trial, infertility
Oxolife has announced positive phase 2 clinical data on its fertility pill OXO-001 at the European Society of Human Reproduction …
AstraZeneca’s Tagrisso gains EU approval for lung cancer treatment
July 8, 2024Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer
AstraZeneca has announced that the EU’s European Commission (EC) has approved Tagrisso (osimertinib), with the addition of pemetrexed and platinum-based …
GSK and CureVac to restructure collaboration into licensing agreement
July 3, 2024Sales and Marketing CureVac, GSK, Immunology, License Agreement, collaboration
GSK and CureVac have announced that they have restructured their existing collaboration into a license agreement, which is intended to …
Eli Lilly’s Kisunla approved by FDA for Alzheimer’s treatment
July 3, 2024Medical Communications Alzheimer's, Eli Lilly, Kisunla, Neurology
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt, 350mg/20ml once-monthly injection for …
Arcturus Therapeutics provides update on OTC deficiency and CF programmes
July 2, 2024Research and Development Arcturus Therapeutics, OTC, Pharmacy, clinical trials, cystic fibrosis
Arcturus Therapeutics has announced mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase (OTC) deficiency, and ARCT-032, …
NeuroSense shares update from ALS treatment trial
July 2, 2024Research and Development NeuroSense, Neurology, als, clinical trial
NeuroSense has announced new statistically significant results from the 12-month analysis of its PARADIGM phase 2b study which assessed PrimeC …
Sanofi shares results from phase 2 trial for frexalimab in MS treatment
July 1, 2024Research and Development MS, Neurology, Sanofi, multiple sclerosis
Sanofi has announced new phase 2 trial data for its CD40L monoclonal antibody, frexalimab, for the treatment of patients with …
EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention
July 1, 2024Research and Development COVID-19, EMA, Infections and infestations, coronavirus
AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for sipavibart under the …
Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China
June 28, 2024Business Services Alzheimers, Biogen, Eisai, Leqembi, Neurology, lecanemab
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a treatment for mild cognitive impairment …
AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment
June 28, 2024Medical Communications AbbVie, CHMP, EMA, Oncology, follicular lymphoma
AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …
IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer
June 27, 2024Research and Development IDEAYA Biosciences, Oncology, bladder cancer, clinical trials, oncology
Precision medicine oncology company IDEAYA Biosciences has announced that the first patient in the IDEAYA-sponsored phase 1 trial has been …
Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA
June 27, 2024Research and Development MimiVax, Oncology, Orphan Drug Designation, Roswell Park Comprehensive Cancer Center, immunotherapies, oncology
The US Food and Drug Administration (FDA) has granted an expanded Orphan Drug Designation (ODD) for brain cancer immunotherapy SurVaxM, …
Abcuro completes enrolment for phase 2/3 IBM treatment trial
June 26, 2024Research and Development Abcuro, Musculo-skeletal disorder, ibm, inclusion body myositis, ulviprubart
Abcuro has announced that it has completed the enrolment for its registrational phase 2/3 MUSCLE clinical trial, which aims to …
AskBio initiates phase 2 Parkinson’s trial recruitment
June 26, 2024Research and Development AskBio, Neurology, Parkinson's disease, clinical trial
Asklepios BioPharmaceutical (AskBio), a subsidiary of Bayer, has announced that it has initiated the recruitment for its phase 2 REGENERATE-PD …
AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment
June 25, 2024Medical Communications AstraZeneca, Oncology, Tagrisso, chemotherapy, lung cancer
AstraZeneca has announced that Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy has been approved in Japan for the …
ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial
June 25, 2024Research and Development Emmes Group, ILiAD Biotechnologies, Infections and infestations, Vaccine, whooping cough
ILiAD Biotechnologies has announced that it has selected Emmes Group to conduct the upcoming phase 3 trials of its lead …
GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment
June 24, 2024Medical Communications EMA, GSK, Jemperli, Oncology, endometrial cancer
GSK has announced that the European Medicines Agency (EMA) has accepted the application to expand the use of Jemperli (dostarlimab) …
Vertex shares results from phase 1/2 trial of type 1 diabetes treatment
June 24, 2024Research and Development Diabetes, Vertex pharmaceuticals, clinical trial, diabetes
Vertex Pharmaceuticals has announced new data from its phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated …
Latest content
FibroFind appoints Lee Borthwick as CEO
